Psoriatic arthritis therapy: NSAIDs and traditional DMARDs

Annals of the Rheumatic Diseases

Volumn 64, Issue SUPPL. 2, 2005, Pages

  Nash, P ^a,b   Clegg, D O ^c  

^a NAMBOUR GENERAL HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AURANOFIN; AUROTHIOMALATE; AZATHIOPRINE; BROMOCRIPTINE; CHLORMETHINE; CHLOROQUINE; CIMETIDINE; CLADRIBINE; COLCHICINE; CYCLOSPORIN; CYCLOSPORIN A; ETRETINATE; FUMARIC ACID; GLUCOCORTICOID; GOLD; HYDROXYCHLOROQUINE; LEFLUNOMIDE; MERCAPTOPURINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PEPTIDE T; RETINOL DERIVATIVE; SALAZOSULFAPYRIDINE; SOMATOSTATIN;

ALOPECIA; CHEILITIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; EPISTAXIS; ERYTHRODERMA; EXFOLIATIVE DERMATITIS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; LEUKOPENIA; LIVER CIRRHOSIS; MOUTH DISEASE; MYALGIA; NAUSEA; PHOTOSENSITIVITY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; PUSTULE; SIDE EFFECT; SKIN DISEASE; SKIN TOXICITY; STOMATITIS; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; GLUCOCORTICOIDS; HUMANS; TREATMENT OUTCOME;

EID: 14244269340     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.030783     Document Type: Conference Paper

References (50)

1. Husted JA, Gladman DD, Farewell VT, Cook RJ. Health related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001;45:151-8.
2. Rahman P, Nguyen E, Cheung C, Schentag CT, Gladman DD. Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. J Rheumatol 2001;28:1041-4.
3. Mease PJ, Antoni CE. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 2005;64(suppl II):ii78-82.
4. Bellamy N. Science of assessments. Ann Rheum Dis 2005;64(suppl II):ii42-5.
5. Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64(suppl II):ii49-54.
6. van de Heijde D, Sharp J, Wassenberg S, Gladman DD. Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis 2005;64(suppl II):ii61-4.
7. Sarzi-Puttini P, Santandrea S, Boccassini L, Panni B, Caruso I. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 2001;19:S17-S20.
8. Meyerhaff JO. Exacerbation of psoriasis with meclofenamate. N Engl J Med 1983;5:309-496.
9. Clark DW, Coulter DM. Psoriasis associated with rofecoxib. Arch Dermatol 2003;139:1223.
10. Ben-Chetrit E, Rubinow A. Exacerbation of psoriasis by ibuprofen. Cutis 1986;38:45.
11. Maksymowych WP, Inman RD, Gladman D, Thomson G, Stone M, Karsh J, et al. Spondyloarthritis Research Consortium of Canada (SPARCC). Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spandyloarthritis. J Rheumatol 2003;30:1356-63.
12. Baker H, Ryan TJ. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol 1968;80:771-93.
13. Farr M, Kitas GD, Waterhouse L, Jubb R, Felix-Davies D, Bacon PA. Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br J Rheumatol 1990;29:46-9.
14. Gupta AK, Grober JS, Hamilton TA, Ellis CN, Siegel MT, Voorhees JJ, et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 1995;22:894-8.
15. Fraser SM, Hopkins R, Hunter JA, Neumann V, Capell HA, Bird HA. Sulphasolazine in the management of psoriatic arthritis. Br J Rheumatol 1993;32:923-5.
16. Dougados M, vam der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
17. Rahman P, Gladman DD, Cook RJ. The use of sulfasolazine in psoriatic arthritis: a clinic experience. J Rheumatol 1998;25:1957-61.
18. Cambe B, Goupille P, Kuntz J, Tebib J, Leote F, Bregeon C. Sulphasalizine in psoriatic arthritis; a randomized multicentre placebo controlled trial. Br J Rheumatol 1996;35:664-8.
19. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013-20.
20. Clegg DO, Redo DJ, Abdellalif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of me seronegative spandylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999;42:2325-9.
21. Black RL, O'Brien WM, VanScott EJ, Aurbach R, Eisen AZ, Bunim JJ. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA 1964;189:743-7.
22. Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27:376-81.
23. Espinaza LR, Zakraoui L, Espinoza CG, Gutierrez F, Jara LJ, Silveira LH, et al. Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol 1992;19:872-7.
24. Abu-Shakra M, Gladman DD, Thorne JC, Long J, Gough J, Farewell VT. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995;22:241-5.
25. Wallina U, Stander K, Barta U. Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis-short- and long-term loxicity in 104 patients. Clin Rheumatol 2001;20:406-10.
26. Carette S, Calin A, McCafferty JP, Wallin BA. A double-blind placebo-controlled study of auranofin in patients with psoriatic arthritis. Arthritis Rheum 1989;32:158-65.
27. Dorwart BB, Gall EP, Schumacher HR, Krauser RE. Chrysotherapy in psoriatic arthritis. Efficacy and toxicity compared to rheumatoid arthritis. Arthritis Rheum 1978;21:513-15.
28. Palit J, Hill J, Capell HA, Carey J, Daunt SO, Cawley MI, et al. A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br J Rheumatol 1990;29:280-3.
29. Mader R, Gladman DD, Long J, Gough J, Farewell VT. Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis? Clin Invest Med 1995;18:139-43.
30. Lacaille D, Stein HB, Raboud J, Klinkhoff AV. Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate? J Rheumatol 2000;27:1922-7.
31. Gomez-Vaquera C, Rodriguez-Moreno J, Ros S, Marcos R, Fiter J, Roig-Escofet D. Termination of disease-modifying drugs in psoriatic arthritis: study of 109 courses of treatment. Br J Rheumatol 1996;35:564-7.
32. Fax RI. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol 1998;53:20-6.
33. Scarpa R, Manguso F, Oriente P et al. Leflunomide in psoriatic polyarthritis: an Italian pilot study. Arthritis Rheum 2001;44:592.
34. Liang GC, Barr WG. Long term followup of the use of leflunomide in recalcitrant psoriatic arthritis and psoriasis. Arthritis Rheum 2001;44:S121.
35. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, et al. Treatment of Psoriatic Arthritis Study Group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939-50.
36. Baum J, Hurd E, Lewis D, Ferguson JL, Ziff M. Treatment of psoriatic arthritis with 6-mercaptopurine. Arthritis Rheum 1973;16:139-47.
37. Levy J, Paulus HE, Barnett EV, Sokoloff M, Bangert R, Pearson CM. A double-blind controlled evaluation of azathioprine treatment in rheumatoid arthritis and psoriatic arthritis. Arthritis Rheum 1972;15:116-17.
38. Steinsson K, Jonsdottir I, Valdimarsson H. Cyclosporin A in psoriatic arthritis: an open study. Ann Rheum Dis 1990;49:603-6.
39. Spadara A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A. Comparison of cyclosparin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995;13:589-93.
40. Mazzanti G, Coloni L, De Sobbata G, Paladini G. Methotrexate and cyclosparin combined therapy in severe psoriatic arthritis. A pilot study. Acta Derm Venereol Suppl (Stockh) 1994;186:116-17.
41. Gladman DD, Blake R, Brubacher B, Farewell VT. Chloroquine therapy in psoriatic arthritis. J Rheumatol 1992;19:1724-6.
42. Price R, Gibson T. D-penicillamine and psoriatic arthropathy. Br J Rheumatol 1986;25:228.
43. Wahba A, Cohen H. Therapeutic trials with oral colchicine in psoriasis. Acta Dermatol Venereol 1980;60:515-20.
44. Seideman P, Fjellner B, Johannesson A. Psoriatic arthritis treated with oral colchicine. J Rheumatol 1987;14:777-9.
45. McKendry RJ, Kraag G, Seigel S, ol-Awadhi A. Therapeutic value of colchicine in the treatment of patients with psoriatic arthritis. Ann Rheum Dis 1993;52:826-8.
46. Klinkhoff AV, Gertner E, Chalmers A, Gladman DD, Stewart WD, Schachter GD, et al. Pilot study of etretinate in psoriatic arthritis. J Rheumatol 1989;16:789-91.
47. Goupille P, Soutif D, Valat JP. Treatment of psoriatic arthropathy. Semin Arthritis Rheum 1992;21:355-67.
48. Wilfert H, Honigsmann H, Steiner G, Smolen J, Wolff K. Treatment of psoriatic arthritis by extracorporeal photochemotherapy. Br J Dermatol 1990;122:225-32.
49. Vahlquist C, Larsson M, Emerudh J, Berlin G, Skogh T, Vahlquist A. Treatment of psoriatic arthritis with extracorporeal photochemotherapy and conventional psoralen-ultraviolet A irradiation. Arthritis Rheum 1996;39:1519-23.
50. Matucci-Cerinic M, Lotti T, Cappugi P, Boddi V, Fattorini L, Panconesi E. Somatostatin treatment of psoriatic arthritis. Int J Dermatol 1988;27:56-8.